This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The purpose of this study is to compare the effects of subcutaneous recombinant interleukin-2 (SC rIL-2) and no SC rIL-2 on disease progression and death over an average follow-up period of 6-7 years in patients with HIV-1 infection on stable antiretroviral therapy who have a CD4+ count between 50 and 299 cells mm3 and a viral load <10,000 copies/ml. The primary objective is to compare the rate of disease progression (new or recurrent events) or death, over an average of 6-7 years of follow-up (range 5-8 years) in groups of patients randomly assigned to receive SC rIL-2 or no rIL-2 (control). Both randomized treatment groups must receive combination antiretroviral treatment, with the choice of combination therapy at the discretion of the treating clinician.
Showing the most recent 10 out of 570 publications
